Bing Chen
Impact in
- Cancer Research top 0.5%
- Cancer-related molecular mechanisms research
- MicroRNA in disease regulation
- Cancer, Hypoxia, and Metabolism
- Molecular Biology top 5%
- Circular RNAs in diseases
- RNA modifications and cancer
- RNA Research and Splicing
- Extracellular vesicles in disease
Papers in
-
- Cancer-related molecular mechanisms research 29
- MicroRNA in disease regulation 22
-
- Circular RNAs in diseases 26
- RNA modifications and cancer 17
- RNA Research and Splicing 9
- Ubiquitin and proteasome pathways 4
Bing Chen
71 papers receiving 2.9k citations
Hit Papers
Peers
Comparison fields: 5 of 101
- Cancer Research 1.9k
- Molecular Biology 2.3k
- Oncology 326
- Immunology 233
- Geriatrics and Gerontology 39
Countries citing papers authored by Bing Chen
This map shows the geographic impact of Bing Chen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bing Chen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bing Chen more than expected).
Fields of papers citing papers by Bing Chen
This network shows the impact of papers produced by Bing Chen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bing Chen. The network helps show where Bing Chen may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Bing Chen, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 1 | |
| 2 | 2025 | 2 | |
| 3 | 2025 | 0 | |
| 4 | 2024 | 6 | |
| 5 | 2024 | 2 | |
| 6 | 2024 | 3 | |
| 7 | 2023 | 38 | |
| 8 | 2023 | 62 | |
| 9 | 2022 | 62 | |
| 10 | 2022 | 131 | |
| 11 | 2021 | 16 | |
| 12 | 2020 | 39 | |
| 13 | 2020 | 48 | |
| 14 | 2019 | 107 | |
| 15 | circRNA_0025202 Regulates Tamoxifen Sensitivity and Tumor Progression via Regulating the miR-182-5p/FOXO3a Axis in Breast Cancer Hit paper breakdown → | 2019 | 340 |
| 16 | 2019 | 60 | |
| 17 | 2019 | 65 | |
| 18 | 2019 | 28 | |
| 19 | 2017 | 7 | |
| 20 | 2016 | 13 |
About Bing Chen
Bing Chen is a scholar working on Cancer Research, Molecular Biology, Immunology and Allergy, Pathology and Forensic Medicine and Pulmonary and Respiratory Medicine, having authored 74 papers that have together received 2.9k indexed citations. Recurring topics across this work include Cancer-related molecular mechanisms research (29 papers), Circular RNAs in diseases (26 papers), MicroRNA in disease regulation (22 papers), RNA modifications and cancer (17 papers), RNA Research and Splicing (9 papers), Ferroptosis and cancer prognosis (5 papers), Ubiquitin and proteasome pathways (4 papers) and Cancer Mechanisms and Therapy (4 papers). The work is most often cited by research in Cancer Research (1.9k citations), Molecular Biology (2.3k citations), Oncology (326 citations), Immunology (233 citations) and Geriatrics and Gerontology (39 citations). Bing Chen has collaborated with scholars based in China, United States and United Kingdom. Frequent co-authors include Qifeng Yang, Wenjing Zhao, Ning Zhang, Yiran Liang, Yaming Li, Hanwen Zhang, Xiaojin Song, Ying Liu, Xiaolong Wang and Lijuan Wang. Their work appears in journals such as Cell Death and Disease, Oncogene, Advanced Science, Frontiers in Oncology and Molecular Therapy — Nucleic Acids.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.